On March 13, 2019, Koert VandenEnden, Chief Accounting Officer of Arbutus Biopharma Corporation, announced his intention to resign as Chief Accounting Officer of the Company in order to pursue a new opportunity. Mr. VandenEnden’s resignation will be effective March 31, 2019. David C. Hastings, the Company’s Chief Financial Officer, has been appointed as the Company’s principal accounting officer, effective as of Mr. VandenEnden’s resignation on March 31, 2019. Mr. Hastings will serve as the Company’s principal accounting officer in addition to continuing his role as the Company’s Chief Financial Officer.